Daily Sepsis Research Analysis
Three impactful studies advance sepsis science along complementary axes: (1) a rigorous human transcriptomic analysis shows that the causative pathogen explains substantial variance in the host response during bloodstream infection and yields an externally validated 8-gene classifier; (2) a pediatric RCT demonstrates that targeting lower mean blood pressure in septic shock is non-inferior for mortality while reducing vasoactive exposure and ARDS; (3) a mechanistic mouse study reveals opposing ro
Summary
Three impactful studies advance sepsis science along complementary axes: (1) a rigorous human transcriptomic analysis shows that the causative pathogen explains substantial variance in the host response during bloodstream infection and yields an externally validated 8-gene classifier; (2) a pediatric RCT demonstrates that targeting lower mean blood pressure in septic shock is non-inferior for mortality while reducing vasoactive exposure and ARDS; (3) a mechanistic mouse study reveals opposing roles of plasma carboxypeptidases (CPN vs. CPB2) in E. coli sepsis, refining complement-focused therapeutic strategies.
Research Themes
- Pathogen-informed precision diagnostics in sepsis
- Hemodynamic targets in pediatric septic shock
- Complement regulation and enzymatic control of inflammatory injury in sepsis
Selected Articles
1. Pathogen-specific host response in critically ill patients with blood stream infections: a nested case-control study.
In a rigorously designed, multi-platform transcriptomic study of 341 critically ill patients, the causative pathogen accounted for 41.8% of host blood transcriptomic variance in bloodstream infection. Streptococcal BSI elicited the strongest innate/adaptive signatures and an 8-gene classifier generalized across Streptococcus species and external cohorts, while E. coli and S. aureus BSIs showed distinct cytokine/systemic inflammation and endothelial activation profiles, respectively.
Impact: This work advances precision sepsis by linking pathogen identity to distinct, validated host-response signatures and providing a practical 8-gene classifier for streptococcal BSI.
Clinical Implications: Transcriptomic classifiers and targeted biomarker panels could enable early pathogen-class inference to tailor antimicrobial choices, timing of source control, and adjunctive therapies (e.g., endothelial stabilizers in S. aureus BSI).
Key Findings
- The causative pathogen explained 41.8% of host blood transcriptomic variance in BSI.
- Streptococcal BSI showed the strongest innate and adaptive immune activation and supported an 8-gene classifier validated across species and external cohorts.
- E. coli BSI aligned with the strongest cytokine/systemic inflammation signals, whereas S. aureus BSI showed the strongest endothelial activation signatures.
Methodological Strengths
- Discovery and independent validation using RNA-seq and microarray across multiple cohorts
- Integration of transcriptomics with 20 plasma biomarkers to triangulate pathway activation
Limitations
- Observational design with sampling within ±1 day of culture may be influenced by early treatments and disease trajectory
- Generalizability to non-ICU or polymicrobial infections requires further study; clinical utility of classifiers needs prospective testing
Future Directions: Prospective, real-time testing of pathogen-classifier-guided management to assess impact on time-to-appropriate therapy, source control, and outcomes; expansion to polymicrobial and fungal BSIs.
BACKGROUND: Knowledge of the contribution of the pathogen to the heterogeneity of the host response to infection is limited. We aimed to compare the host response in critically ill patients with a bloodstream infection (BSI). METHODS: RNA profiles were determined in blood obtained between one day before and after a positive blood culture. Differential expression and pathway analyses were performed on independent patients' samples by RNA sequencing (discovery) or microarray (validation). Additional patients were included for the discovery and validation of transcriptome classifiers of pathogen-specific BSIs. Twenty biomarkers reflecting key host response pathways were measured in blood. FINDINGS: We included 341 patients, among which 255 with BSI, 25 with viral infection and 61 non-infectious controls. The cultured pathogen explained 41·8% of the blood transcriptomic variance in patients with BSI. Gene set enrichment analysis showed a global resemblance between monomicrobial BSIs caused by Streptococcus, Staphylococcus aureus and Escherichia coli, which were clearly different from BSI caused by coagulase-negative staphylococci or Enterococcus. BSI by Streptococcus was associated with the highest number of differentially expressed genes, indicating strong innate and adaptive immune activation. An eight-gene streptococcal classifier performed well across different Streptococcus species, and was validated in external cohorts. Plasma biomarker profiling showed that E. coli BSI was associated with the strongest response in the cytokine and systemic inflammation domain, and S. aureus BSI with the strongest endothelial cell activation. INTERPRETATION: The causative pathogen explains a substantial part of the heterogeneity of the host response in critically ill patients with BSI. FUNDING: Center for Translational Molecular Medicine and the European Commission.
2. Fifth Centile Versus 50th Centile Mean Blood Pressure Targets in Pediatric Septic Shock: A Randomized Controlled Trial.
In a single-center randomized noninferiority trial of 144 children with septic shock, targeting the 5th versus 50th percentile mean blood pressure resulted in similar 28-day mortality. The lower target reduced norepinephrine use, vasoactive duration, Vasoactive-Inotropic Score, and ARDS prevalence without increasing adverse events.
Impact: Addresses a guideline-relevant hemodynamic target with randomized data, supporting safer de-escalation of vasoactive therapy in pediatric septic shock.
Clinical Implications: Clinicians can consider lower MBP targets (5th percentile) when titrating vasopressors in pediatric septic shock to minimize drug exposure and ARDS risk without compromising short-term mortality.
Key Findings
- 28-day all-cause mortality did not differ between 5th and 50th percentile MBP targets (16.9% vs 23.2%; p=0.41).
- The 50th percentile group had higher norepinephrine use (85% vs 67%; p=0.04) and longer vasoactive duration (30.4±13.3 vs 18.8±10.8 hours; p=0.001).
- ARDS prevalence was significantly higher in the 50th percentile group (32.8% vs 16.9%; p=0.02).
Methodological Strengths
- Randomized controlled, prespecified noninferiority design
- Clinically relevant endpoints including mortality, vasoactive exposure, and ARDS
Limitations
- Single-center, open-label design may limit generalizability and introduce performance bias
- Conducted in an Indian tertiary PICU; external validation across diverse settings is needed
Future Directions: Multicenter, blinded or protocolized trials to confirm safety/effectiveness of lower MBP targets and to assess long-term neurodevelopmental outcomes.
OBJECTIVES: Hypotension is common in septic children, mean blood pressure (MBP) guides vasoactive agent titration. However, the Surviving Sepsis Guidelines for children were unable to recommend whether to target the 5th or 50th MBP percentile for septic shock. We aim to compare two MBP targets (5th vs. 50th percentile) for titrating vasoactive agents in septic shock patients. DESIGN: Single-center, open-label, randomized noninferiority trial. SETTING: It was conducted in a tertiary care PICU in India from April 2021 to March 2024. PATIENTS: Patients 1 month to 16 years old with septic shock unresponsive to fluids and requiring vasopressors. INTERVENTIONS: Children with septic shock were randomly assigned to either the 5th or 50th percentile MBP group, with vasopressor treatment adjusted to maintain the target blood pressure (BP) for each group. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day all-cause mortality. Secondary outcomes included PICU/hospital stay, duration of vasoactive use, vasopressor-related adverse events, need for continuous renal replacement therapy (CRRT), invasive ventilation, and prevalence of acute respiratory distress syndrome (ARDS). A total of 144 children were enrolled. At 28 days, mortality did not differ significantly between groups: 16.9% (12/71) in the 5th centile group vs. 23.2% (17/73) in the 50th centile group ( p = 0.41; risk difference, 6.3; 95% CI, -6.9 to 19.2). Norepinephrine use was higher in the 50th centile group (85% vs. 67%; p = 0.04). Vasoactive duration was longer in the 50th centile group (30.4 ± 13.3 vs. 18.8 ± 10.8; p = 0.001). The Vasoactive-Inotropic Score was also higher (64.0 ± 35.7 vs. 45.2 ± 29.6; p = 0.001). ARDS prevalence was significantly higher in the 50th centile group (32.8% vs. 16.9%; p = 0.02). No significant differences were found in other secondary outcomes like length of stay, ventilation duration, need for CRRT, or adverse events. CONCLUSIONS: Targeting a lower MBP (5th vs. 50th centile) in septic shock showed no significant difference in 28-day mortality. This suggests a lower BP target may be safe, reducing vasoactive drug use and related side effects.
3. Deficiencies of carboxypeptidase N and carboxypeptidase B2 have opposite effects in a virulent mouse E. coli sepsis model.
In a virulent E. coli sepsis mouse model, CPB2 deficiency prolonged survival despite higher bacterial loads, whereas CPN deficiency shortened survival despite lower bacterial loads. These opposing phenotypes support CPN as a first-line regulator against excessive C3a/C5a and suggest CPB2 mainly inactivates C3a locally, with therapeutic implications for complement modulation.
Impact: Reveals enzyme-specific and opposing roles in complement control during sepsis, informing selective therapeutic targeting of carboxypeptidases.
Clinical Implications: Complement-modulating strategies in sepsis may benefit from enhancing CPN activity or avoiding indiscriminate inhibition of CPB2, acknowledging context-specific effects on C3a/C5a biology.
Key Findings
- CPB2 deficiency prolonged survival, while CPN deficiency shortened survival compared to wild-type mice.
- Double-deficient mice displayed higher liver damage and thrombocytopenia; CPN-deficient mice were leukopenic.
- Bacterial load increased in CPB2 and double-deficient mice, but decreased in CPN-deficient mice.
Methodological Strengths
- Genetic knockout models enabling causal inference on enzyme function in vivo
- Comprehensive phenotyping including survival, organ injury, hematology, and bacterial burden
Limitations
- Murine model findings may not directly translate to human sepsis; pathogen and dose model-specific effects are possible
- Complement peptide levels (e.g., C3a/C5a) and downstream signaling were inferred rather than directly quantified in the abstract
Future Directions: Quantify complement effectors and test pharmacologic modulators of CPB2/CPN in diverse sepsis models; evaluate safety/efficacy in large animals before translation.
BACKGROUND: Two basic carboxypeptidases circulate in plasma, procarboxypeptidase B2, which is activated to carboxypeptidase B2 (CPB2), and carboxypeptidase N (CPN). These enzymes inactivate complement anaphylatoxins, C3a and C5a, with high C5a being toxic. OBJECTIVES: To test the hypothesis that these carboxypeptidases would affect Escherichia coli sepsis in mice differently because CPN is constitutively active while procarboxypeptidase B2 beeds to be locally activated. METHODS: Mice deficient in CPB2, CPN, or both enzymes were infected with E. coli and their health and survival was compared to wild-type mice. Clinical chemistry, complete blood count, and bacterial load were assessed. RESULTS: Lack of CPB2 prolonged survival while lack of CPN shortened survival compared to wild-type mice. Liver damage was higher in double deficient mice that were also thrombocytopenic, and CPN-deficient mice were leukopenic. Bacterial load was higher in CPB2 and double deficient mice and lower in CPN-deficient mice. CONCLUSION: CPN provides first-line protection against excessive C3a and C5a, accounting for the shortened survival in CPN-deficient mice in this sepsis model, despite reduced E. coli load. CPB2 serves a supportive role by primarily inactivating C3a locally. Apparently, CPB2 deficiency led to enhanced local levels of protective C3a and prolonged survival in the CPB2-deficient mice in this model, while the lack of CPN exacerbated the infection.